LifeVantage Corp. Stock Hits New 52-Week Low at USD 8.10

LifeVantage Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 8.10 on October 29, 2025. This marks a significant decline for the stock, which has underperformed compared to the S&P 500, generating negative returns of -36.92% over the past year, while the index has seen a gain of 18.33%.
Despite this downturn, LifeVantage Corp. has reported a notable increase in net profit, which grew by 83.16% to USD 5.43 million in the first half of the year. The company also boasts a strong return on equity (ROE) of 28.30%, indicating effective management efficiency. Additionally, the firm maintains a low debt-to-equity ratio of -0.53, reflecting a solid financial position.

However, the company has faced challenges with long-term growth, as its operating profit has declined at an annual rate of -5.22% over the past five years. The stock's price-to-book ratio stands at 4.19, suggesting a premium valuation relative to its book value. With institutional holdings at 55.54%, LifeVantage Corp. continues to attract significant interest from larger investors, who have increased their stakes by 20.76% in the last quarter.